GoAI
Get started
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc.

VIR

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$9.78

+$0.57 · +6.19%

Aug 21, 4:00 PM ET

VIR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

2

Overpriced

Momentum

63

Gaining

Sentiment

68

Bullish

Risk resilience

47

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Marianne De Backer
Listed since
Oct 11, 2019
Employees
367

Market position

Day range

Current $9.78

52-week range

Current $9.78

Open
$9.31
Previous close
$9.21
Volume
1.76M
0.99× average
Average volume
1.77M
Average daily volume
Market cap
1.65B USD
Beta
1.59
Market reference 1
50-day average
$9.3705
+4.37% above average
200-day average
$8.3032
+17.79% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
788.08M USD
P/E (TTM)
-5.29×
P/B (TTM)
1.67×
P/S (TTM)
5.44×
EV / EBITDA
-1.85×
Earnings yield
-52.44%
Free cash flow yield
-47.48%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
170.01%
Operating margin
-88.97%
Net margin
-83.00%
Return on equity
-57.23%
Return on assets
-43.68%
Return on invested capital
-50.94%

Financial health

Debt / equity
0.09×
Current ratio
5.54×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends171%-180%-531%-882%Gross margin, FY2021: 53.09%Gross margin, FY2022: 61.57%Gross margin, FY2023: -564.69%Gross margin, FY2024: -545.03%Gross margin, FY2025: 82.92%Operating margin, FY2021: 38.41%Operating margin, FY2022: 51.56%Operating margin, FY2023: -794.04%Operating margin, FY2024: -791.27%Operating margin, FY2025: -682.68%Net margin, FY2021: 48.25%Net margin, FY2022: 31.92%Net margin, FY2023: -713.69%Net margin, FY2024: -703.40%Net margin, FY2025: -638.87%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 53.09%. Gross margin FY2022 61.57%. Gross margin FY2023 -564.69%. Gross margin FY2024 -545.03%. Gross margin FY2025 82.92%. Operating margin FY2021 38.41%. Operating margin FY2022 51.56%. Operating margin FY2023 -794.04%. Operating margin FY2024 -791.27%. Operating margin FY2025 -682.68%. Net margin FY2021 48.25%. Net margin FY2022 31.92%. Net margin FY2023 -713.69%. Net margin FY2024 -703.40%. Net margin FY2025 -638.87%.

Income trends

Revenue

68.56M USD-7.61%

Operating income

−468.02M USD+20.29%

Net income

−437.99M USD+16.09%
Income trends across reported periods1.85B USD925.77M USD5.73M USD−914.32M USDRevenue, FY2021: 1.1B USDRevenue, FY2022: 1.62B USDRevenue, FY2023: 86.18M USDRevenue, FY2024: 74.21M USDRevenue, FY2025: 68.56M USDOperating income, FY2021: 420.75M USDOperating income, FY2022: 833.07M USDOperating income, FY2023: −684.31M USDOperating income, FY2024: −587.17M USDOperating income, FY2025: −468.02M USDNet income, FY2021: 528.58M USDNet income, FY2022: 515.84M USDNet income, FY2023: −615.06M USDNet income, FY2024: −521.96M USDNet income, FY2025: −437.99M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.1B USD. Revenue FY2022 1.62B USD. Revenue FY2023 86.18M USD. Revenue FY2024 74.21M USD. Revenue FY2025 68.56M USD. Operating income FY2021 420.75M USD. Operating income FY2022 833.07M USD. Operating income FY2023 −684.31M USD. Operating income FY2024 −587.17M USD. Operating income FY2025 −468.02M USD. Net income FY2021 528.58M USD. Net income FY2022 515.84M USD. Net income FY2023 −615.06M USD. Net income FY2024 −521.96M USD. Net income FY2025 −437.99M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue68.56M USD74.21M USD86.18M USD1.62B USD1.1B USD
Cost of goods sold11.71M USD478.65M USD572.83M USD620.97M USD513.87M USD
Gross profit56.85M USD−404.44M USD−486.65M USD994.83M USD581.54M USD
Research and development432.8M USD506.5M USD579.72M USD474.65M USD448.01M USD
Selling, general, and administrative92.07M USD————
Operating expenses524.87M USD182.73M USD197.66M USD161.76M USD160.79M USD
Interest income40.24M USD71.81M USD86.99M USD28.09M USD439K USD
Depreciation and amortization11.68M USD14.56M USD19.45M USD6.78M USD5.81M USD
Operating income−468.02M USD−587.17M USD−684.31M USD833.07M USD420.75M USD
Net income−437.99M USD−521.96M USD−615.06M USD515.84M USD528.58M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-763.84%
11 comparable reports
Latest EPS result
0.47
Estimate 0.33 · Beat by 41.31%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.6-0.03-0.67-1.3Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual -0.76, estimate -0.85, surprise +10.59%, Beat. Q2 2025, reported May 7, 2025: actual -0.88, estimate -0.83, surprise -6.02%, Miss. Q3 2025, reported Aug 6, 2025: actual -0.8, estimate -0.72, surprise -11.11%, Miss. Q4 2025, reported Nov 5, 2025: actual -1.17, estimate -0.7, surprise -67.14%, Miss. Q1 2026, reported Feb 23, 2026: actual -0.31, estimate -0.42, surprise +26.19%, Beat. Q2 2026, reported May 6, 2026: actual -0.85, estimate -0.01, surprise -8400.00%, Miss. Q3 2026, reported Aug 5, 2026: actual 0.47, estimate 0.333, surprise +41.31%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.735, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates258.06M165.66M73.26M-19.15MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 12.37M USD, estimate 8.14M USD, surprise +52.01%, Beat. Q2 2025, reported May 7, 2025: actual 1.79M USD, estimate 8.59M USD, surprise -79.12%, Miss. Q3 2025, reported Aug 6, 2025: actual 1.21M USD, estimate 2.72M USD, surprise -55.40%, Miss. Q4 2025, reported Nov 5, 2025: actual 240K USD, estimate 19.91M USD, surprise -98.79%, Miss. Q1 2026, reported Feb 23, 2026: actual 64.07M USD, estimate 19.91M USD, surprise +221.87%, Beat. Q2 2026, reported May 6, 2026: actual -29K USD, estimate 55.49M USD, surprise -100.05%, Miss. Q3 2026, reported Aug 5, 2026: actual 238.95M USD, estimate 135.88M USD, surprise +75.85%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 865.13K USD, surprise —, Comparison unavailable.

VIR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding VIR

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
69.42M
Weight
0.06%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
47.81M
Weight
0.42%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
41.97M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
30.25M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
28.61M
Weight
0.04%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
17.47M
Weight
0.04%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
12.13M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
10.53M
Weight
0.07%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%

Continue in GoAI

Research VIR

research.disclaimer